Curcumin protects against lipopolysaccharide-induced vasoconstriction dysfunction via inhibition of thrombospondin-1 and transforming growth factor-β1

WEI LU¹, JIAN-PING JIANG², JUE HU³, JUE WANG³ and MING-ZHI ZHENG³

¹Department of Vascular Surgery, Quzhou People’s Hospital, Quzhou, Zhejiang 324000; Departments of ²Clinical Medicine and ³Basic Medical Sciences, Zhejiang Medical College, Hangzhou, Zhejiang 310053, P.R. China

Received May 21, 2014; Accepted November 7, 2014

DOI: 10.3892/etm.2014.2105

Abstract. Sepsis is a complex syndrome characterized by the development of progressive dysfunction in multiple organs. The aim of the present study was to investigate the protective effect of curcumin against lipopolysaccharide (LPS)-induced vasoconstricive dysfunction, and to investigate the possible underlying mechanism. Male Sprague-Dawley rats were randomly divided into the following groups: Control, sepsis and curcumin. A sepsis model was established by an intraperitoneal (i.p.) injection of 5 mg/kg LPS. Thoracic aortic rings obtained from the rats were mounted in an organ bath and the vasoconstriction of the rings was recorded. In addition, the serum E-selectin levels were determined by an enzyme-linked immunosorbent assay. The expression levels of thrombospondin (TSP)-1 and transforming growth factor (TGF)‑β1 in the aortic tissue were detected by immunohistochemistry. Vasoconstriction of the aortic rings was found to significantly decrease in the sepsis rats when compared with the control group. However, curcumin (10 or 20 mg/kg, i.p.) prevented the vasoconstrictive dysfunction induced by LPS. The serum level of E-selectin and the expression levels of TSP-1 and TGF-β1 significantly increased in the sepsis rats when compared with the control group rats; however, the levels decreased significantly following treatment with curcumin (10 or 20 mg/kg). Furthermore, hematoxylin and eosin staining revealed that curcumin alleviated the LPS-induced damage in the aortic tunica intima and tunica media. Therefore, the results indicated that curcumin alleviates LPS-induced vasoconstricive dysfunction in the thoracic aorta of rats. In addition, the inhibition of TSP-1 and TGF-β1 expression may be involved in the mechanism underlying this protective effect.

Introduction

Sepsis is a serious health risk, which may ultimately lead to the failure of multiple organs, including the liver, lungs, cardiovascular system, kidneys and gastrointestinal tract (1-3). In animal models, vascular hyperactivity to vasoconstrictor agents, induced by bacterial lipopolysaccharide (LPS), is an important factor contributing to the eventual circulatory failure (4).

Curcumin, which is derived from the rhizome of the Curcuma longa (turmeric) plant, has been widely used in South East Asia as a food component, but also in the treatment of numerous diseases (5,6). Curcumin has been shown to possesses anti-inflammatory and antioxidative properties (7). In addition, curcumin has been reported to inhibit LPS-induced endothelium barrier disruption by increasing endothelium barrier integrity and inhibiting LPS-mediated nuclear factor (NF)-κB activation and tumor necrosis factor (TNF)-α production (8). However, whether curcumin is able to protect against LPS-induced vascular hypoactivity has not been fully investigated.

Thrombospondin (TSP)-1 is found in platelet β-granules and is produced by a number of cell types, including endothelial cells and vascular smooth muscle cells (9). It has been reported that the expression of TSP-1 is increased on the platelet surface in patients suffering from sepsis, and that polymorphisms of the TSP-1 gene are associated with the progression of sepsis-related organ failure (10). Transforming growth factor (TGF)-β1 is a cytokine that plays a pivotal role in the regulation of the immune/inflammatory response and subsequent tissue repair processes. TGF-β1 has been associated with a number of human diseases; for example, functioning as a promoter of fibrosis (11). Numerous studies have shown that TSP-1 is responsible for a significant proportion of TGF-β1 activation in a variety of organs, including the lungs, pancreas, kidneys, liver and heart (12,13). However, the exact roles of TSP-1 and TGF-β1 in sepsis-associated vasoconstricive dysfunction remain unknown. In addition, whether TSP-1 and TGF-β1 are involved in the protective effect of curcumin on LPS-induced vasoconstricive dysfunction is not clear. In the present study, a LPS-induced sepsis rat model was used to investigate the association between the protective effects of curcumin and the alterations in TSP-1 and TGF-β1 expression.

Correspondence to: Ms. Ming-zhi Zheng, Department of Basic Medical Sciences, Zhejiang Medical College, 481 Bin-Wen Road, Hangzhou, Zhejiang 310053, P.R. China
E-mail: zmjzpdd181@sina.com

Key words: lipopolysaccharide, curcumin, vasoconstriction, thrombospondin-1, transforming growth factor-β1
Materials and methods

Reagents. LPS (from Escherichia coli 055:B5), curcumin, phenylephrine (PE) and acetylcholine (ACh) were obtained from Sigma-Aldrich (St. Louis, MO, USA). DMSO was purchased from Jingchun Biological Technology Co., Ltd. (Shanghai, China). TSP-1 and TGF-β1 antibodies were purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA). A rat E-selectin enzyme-linked immunosorbent assay (ELISA) kit was purchased from Shanghai YuanYe Biological Technology Co., Ltd. (Shanghai, China). Krebs-Henseleit (KH) solution compositions were as follows (in mmol/l): NaCl, 120; NaHCO3, 25; MgSO4, 1.2; CaCl2, 1.25; KCl, 4.5; KH2PO4, 1.2; and glucose, 11.1 (pH 7.4).

Animal preparation. A total of 60 male Sprague-Dawley rats (weight, 220-250 g; age, 40-50 days) were obtained from the Experimental Animal Center of Zhejiang Academy of Medical Sciences (Zhejiang, China), and cared for in compliance with the Guide for the Care and Use of Laboratory Animals (National Institutes of Health, Bethesda, MA, USA; 14). All experimental protocols were approved by the Ethics Committee on Animal Experimentation of Zhejiang Academy of Medical Sciences. The rats were randomly divided into six groups, including the control, LPS [intraperitoneal (i.p.) injection of 5 mg/kg LPS in sterile saline], LPS + curcumin [i.p. injection of 5 mg/kg LPS and 5, 10 or 20 mg/kg curcumin in 10% dimethyl sulfoxide (DMSO)] and curcumin groups (i.p. injection of 20 mg/kg curcumin in 10% DMSO). The control and LPS groups also received an equal amount of 10% DMSO.

Preparation of aortic rings and measurement of vasoconstriction. Aortic rings were prepared using the method described by Fang et al. (7). Briefly, 24 h after the i.p. injection of the respective reagents, all the rats were anesthetized with 3% pentobarbital sodium (60 mg/kg). Then thoracic cavity was opened and the thoracic aorta was surgically removed. The thoracic aorta was cut into 2-3-mm rings, and mounted in an organ bath system (Nanjing MedEase Technology Co., Ltd., Nanjing, China) containing KH solution (95% O2 and 5% CO2, 37°C). Isometric tension was recorded using a data-acquisition system (Nanjing MedEase Technology Co., Ltd.). After 60 min of equilibration at a passive tension of 2 g, the rings were treated three times with KCl (60 mmol/l) to evoke maximal excitability. The integrity of the vascular endothelium was examined by adding PE (10^-6 mol/l) to the organ bath, followed by the addition of ACh (10^-i mol/l). Only tissues that responded to ACh with a >70% reduction of PE-induced vasoconstriction were considered to have an intact endothelium. After washing, PE (10^-6-3x10^-6 mol/l)-induced vasoconstriction was recorded. Contractile responses were expressed as the percentage of the maximum response induced by KCl initially (15). The maximum effect (Emax) and the concentration eliciting 50% of Emax (EC50) were obtained from the cumulative concentration-response curve of PE. Subsequently, pD2 was calculated as -logEC50.

Measurement of serum E-selectin levels. Peripheral rat blood was collected in a tube with coagulant, and centrifuged at 2,200 x g for 10 min at 4°C. Serum supernatant was stored at -80°C until required for analysis. The levels of E-selectin in the serum samples were quantitated using an ELISA, according to the manufacturer’s instructions. E-selectin was determined spectrophotometrically by Tecan Infinite M200 (Tecan Group Ltd., Mannedorf, Switzerland) at an absorbance wavelength of 450 nm.

Immunohistochemistry and histology. Experiments were performed on slices from 10% formalin-fixed tissue embedded in paraffin. Slices were incubated with commercial primary antibodies against TSP-1 (mouse IgG; 1:200; cat. no. sc-59887; Santa Cruz Biotechnology, Inc., Dallas, TX, USA) or TGF-β1 (rabbit IgG; 1:200; cat. no. sc-146; Santa Cruz Biotechnology, Inc.) overnight at 4°C, followed by a horseradish peroxidase-conjugated secondary antibody (1:500; goat anti-mouse IgG, cat. no. sc-2005 or; goat anti-rabbit IgG, cat. no. sc-2004; Santa Cruz Biotechnology, Inc.) at room temperature. Peroxidase activity was visualized with 3,3′-diaminobenzidine and the slices were subsequently counterstained with hematoxylin. Each slice was observed in ten randomly selected
fields, and the percentage of TSP-1-positive or TGF-β1-positive cells in the total cells was calculated. Hematoxylin and eosin (HE) staining was also performed for morphometric analysis.

Statistical analysis. Data are expressed as the mean ± standard error of the mean, and were analyzed by two-way analysis of variance (ANOVA) with a Bonferroni post hoc test or one-way ANOVA with a Newman-Keuls post hoc test, using Prism 5.0 (GraphPad Software, Inc., La Jolla, CA, USA). P<0.05 was considered to indicate a statistically significant difference.

Results

Effects of LPS on PE-induced vasoconstriction in aortic rings. Compared with the control group, the injection of LPS decreased the PE-induced vasoconstriction in the thoracic aortic rings (LPS group: E_max 54.3±0.8% and pD_2 6.29±0.29; vs. control group: E_max 126.0±0.5% and pD_2 7.29±0.10; P<0.01; Fig. 1).

Effects of curcumin on LPS-induced contractile dysfunction in aortic rings. Curcumin (10 or 20 mg/kg) was shown to partly reverse LPS-induced contractile dysfunction (E_max 76.4±4.8 and 93.0±6.9%, respectively; pD_2 6.92±0.18 and 7.05±0.23%, respectively; P<0.05). However, a low concentration of curcumin (5 mg/kg) had no effect on PE-induced vasoconstriction in sepsis rats. Furthermore, curcumin (20 mg/kg) alone had no effect on PE-induced vasoconstriction in the aortic rings (E_max 119.8±4.7%; pD_2 7.25±0.12; P>0.05, vs. control group; Fig. 1).

Effects of curcumin on the LPS-induced increase in E-selectin levels. Compared with the control group, LPS increased the serum E-selectin levels (P<0.01; Fig. 2). However, curcumin (10 or 20 mg/kg) prevented the LPS-induced increase in serum E-selectin levels, although low concentrations of curcumin (5 mg/kg) had no protective effect. Curcumin (20 mg/kg) alone had no effect on serum E-selectin levels when compared with the control group (P>0.05; Fig. 2).

Effects of curcumin on LPS-induced TSP-1 and TGF-β1 overexpression. TSP-1 and TGF-β1 immunoreactivity were observed as a granular immunostaining pattern in the vascular tissues. In the control group, TSP-1- and TGF-β1-positive cells

Figure 3. Immunohistochemical results of TSP-1 protein expression in the thoracic aortic tissues of rats in the (A) control, (B) LPS, (C) LPS + curcumin (5 mg/kg), (D) LPS + curcumin (10 mg/kg), (E) LPS + curcumin (20 mg/kg) and (F) curcumin (20 mg/kg) groups. TPS, thrombospondin; LPS, lipopolysaccharide. The comparison of TSP-1 expression in the thoracic tissue (claybank spots) in the cytoplasm represents positive staining.
were observed in the vascular endothelium and subendothelial layer, but not in the smooth muscle cells. LPS increased the percentage of TSP-1- and TGF-β1-positive cells in the vascular endothelium and subendothelial layer, and positive cells were also observed in the smooth muscle cells. Thus, treatment with curcumin (10 or 20 mg/kg) inhibited LPS-induced TSP-1 and TGF-β1 overexpression (Figs. 3-5).

**Effects of curcumin on LPS-induced vascular injury.** In the control group, the vascular structure of each layer was clear...
and complete. However, the thoracic aortic structure was evidently damaged by LPS, particularly in the endothelium, subendothelial layer and elastic membrane. Treatment with curcumin was shown to protect against LPS-induced vascular injury (Fig. 6).

Discussion

Previous studies have shown that patients who survive severe sepsis have an increased risk of cardiovascular events (16), and sepsis-induced cardiovascular dysfunction is one of the major causes of mortality in sepsis patients (17,18). However, whether aortic contractile function is injured during sepsis remains unclear. The present study demonstrated that PE-induced vasoconstriction of the aortic rings exhibited a significant decline following treatment with LPS for 24 h, suggesting that sepsis may cause aortic vasoconstrictive dysfunction. Previous studies have indicated that a K+ channel abnormality may be an underlying mechanism (4,18). In the present study, LPS was also demonstrated to increase the level of serum E-selectin, which is consistent with results reported by Kim et al (8). E-selectin, which can be synthesized by vascular endothelial cells, has the role of promoting leukocyte rolling along the vascular endothelium. Under normal physiological conditions, there is very little or almost no expression of E-selectin in vascular endothelial cells. LPS is known to activate innate immune responses, resulting in the production of a great variety of inflammatory cytokines (19). Particular in vitro and in vivo stimuli, including inflammatory cytokines (TNF-α) or activated transcription factors (NF-κB), can induce vascular endothelial cells to overexpress E-selectin (20,21). E-selectin molecules on the cell membrane surface may detach or dissolve, becoming soluble (22). Serum soluble E-selectin is an important index of vascular endothelial cell injury (23). Thus, the results of the present study indicate that LPS may lead to aortic endothelial injury.

Curcumin, a natural yellow pigment, is derived from the rhizome of Curcuma longa (24). The compound has been used in traditional Chinese medicine for centuries to treat a variety of diseases, including pulmonary fibrosis, diabetic nephropathy and cervical cancer (25-27). The results of the present study demonstrated that curcumin may have a preventative effect against sepsis-induced vasoconstrictive dysfunction and the increase in serum E-selectin levels. Furthermore, the results of HE staining indicated that curcumin decreased the pathological changes of the aortic vascular tissues induced by sepsis; however, the specific mechanism underlying these effects remains unknown.
TGF-β1 is a matrix glycoprotein with diverse roles in various cellular and physiological processes (28). Sources of TGF-β1 include activated platelets, leukocytes, endothelial cells, vascular smooth muscle cells and fibroblasts (29-31). The expression of TGF-β1 is usually increased at sites of inflammation and is hypothesized to play an important role in multiple biological processes, including thrombosis, wound healing and the immune response (32-36). In animal models of diabetes, TGF-β1 expression was found to increase significantly in the cavernous tissue (37). TGF-β1 expression may impact the prognosis of patients with severe sepsis by inhibiting innate immune function. Furthermore, TGF-β1 deficiency has been reported to have a protective effect in cecal ligation puncture and Escherichia coli injection (i.p.) models of peritoneal sepsis (38). The present study showed that the protein expression of TGF-β1 increased in the aortic tissues of LPS-treated rats, while curcumin was able to inhibit this overexpression.

TGF-β1 is generally considered to be involved in the regulation of inflammation and tissue remodeling following injury (39-41). In normal blood vessels, TGF-β1 inhibits endothelial and vascular smooth muscle cell proliferation (42,43). TGF-β1 has been reported as an important activator of TGF-β1 in diabetic nephropathy. KRFK sequences in TGF-β1, inducing changes in the spatial configuration of the LAP. Subsequently, the receptor binding site on TGF-β1 is exposed and the TSP-1/LAP. Subsequently, the receptor binding site on TGF-β1 is exposed and the TSP‑1 complex is activated (13). In addition, TGF-β1 has been shown to upregulate latent TGF-β1 activation, and in turn, TGF-β1 may facilitate TSP-1 synthesis (44). LPS can strongly induce an increase in the expression of TGF-β1 and acute phase proteins in TGF-β1-transgenic mice (45). Sepsis promotes the release and activity of TGF-β1, thereby causing alveolar epithelial cell dysfunction (46). Furthermore, previous studies have reported that curcumin protects against sepsis-induced acute lung injury by inhibiting the expression of molecules involved in the TGF-β1/SMAD3 pathway (47,48). In keloid fibroblasts, the excessive production of extracellular matrix may be blocked and/or rapidly decreased by curcumin through depression of the TGF-β1/SMAD pathway (49). In the present study, the protein expression of TGF-β1 increased in the aortic tissues during sepsis and curcumin was shown to inhibit this sepsis-induced overexpression, indicating that TGF-β1 may be involved in the protective effect of curcumin against sepsis-induced vasoconstrictor injury.

In summary, the present study has provided experimental evidence demonstrating that curcumin alleviates LPS-induced vasoconstrictor dysfunction in rat thoracic aortas. In addition, inhibition of TSP-1 and TGF-β1 expression may be involved in this protective effect.

Acknowledgements

This study was supported by the Zhejiang Provincial Applied Research Fund of Technology for Public Welfare (no. 2014C37027).

References

1. Vandijck D, Decruyenaere JM and Blot SI: The value of sepsis definitions in daily ICU-practice. Acta Clin Belg 61: 220-226, 2006.

2. Hotchkiss RS and Karl IE: The pathophysiology and treatment of sepsis. N Engl J Med 348: 138-150, 2003.

3. Felbinger TW, Sucher U and Goetz AE: Treating patients with severe sepsis. N Engl J Med 341: 56-57, 1999.

4. Chen SJ, Wu CC, Yang SN, Lin CI and Yen MH: Hyperpolarization contributes to vascular hyperreactivity in rats with lipopolysaccharide-induced endotox shock. Life Sci 68: 659-668, 2000.

5. Jurek JS: Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: a review of preclinical and clinical research. Altern Med Rev 14: 151-159, 2009.

6. Bengmark S, Mesa MD and Gil A: Plant-derived health: the effects of turmeric and curcuminoids. Nutr Hosp 24: 273-281, 2009.

7. Fard AD, Yang F, Zhu L, Shen YL, Wang LL and Chen YY: Curcumin ameliorates high glucose-induced acute vascular endothelial dysfunction in rat thoracic aorta. Clin Exp Pharmacol Physiol 36: 1177-1182, 2009.

8. Kim DC, Ku SK, Lee W and Bae JS: Barrier protective activities of curcumin and its derivative. Inflamm Res 61: 437-444, 2012.

9. Stein JJ, Iwuchukw c, Maier KG and Gahtan V: Thrombospondin-1-induced vascular smooth muscle cell migration and proliferation are functionally independent on microRNA-21. Surgery 155: 228-233, 2014.

10. Gawar M, Dickfeld T, Bogner C, Fehr-Moghadam S and Neumann FJ: Plakoglobin function in multiple organ dysfunction syndrome. Intensive Care Med 23: 379-385, 1997.

11. August P and Suthanthiran M: Transforming growth factor beta signaling, vascular remodeling, and hypertension. N Engl J Med 354: 2721-2723, 2006.

12. Mood SE, Stiel T and Tegtmeier MA: Murphy-Ullrich JE, Ribeiro SM, Lawler J, Hynes RO, Boivin GP and Bouck N: Thrombospondin-1 is a major activator of TGF-beta1 in vivo. Cell 193: 1159-1170, 1998.

13. Yevdokimova N, Wahab NA and Mason RM: Thrombospondin-1 is the key activator of TGF-beta1 in human mesangial cells exposed to high glucose. J Am Soc Nephrol 12: 703-712, 2001.

14. Guide for the Care and Use of Laboratory Animals. National Research Council Committee for the Update of the Guide for the Care and Use of Laboratory Animals, 8th edition, National Academies Press, Washington DC, USA, 2011.

15. Farmer MR, Roberts RE, Gardiner SM and Ralevic V: Effects of in vivo lipopolysaccharide infusion on vasoconstrictor function of rat isolated mesentericy, kidney, and aorta. J Pharmacol Exp Ther 306: 538-545, 2003.

16. Yende S, Linde-Zwirble W, Mayr F, Weissfeld LA, Reiss S and Ang DC: Risk of cardiovascular events in severe sepsis survivors. Am J Respir Crit Care Med 189: 1065-1074, 2014.

17. Coquerel D, Neviere R, Delile E, Mulder P, Marechal X, Montaigne D, Renet S, Remy-Jouet I, Gomez E, Henry JP, do Rego JC, Richard V and Tamion F: Gene deletion of protein tyrosine phosphatase 1B protects against sepsis-induced cardio-vascular dysfunction and mortality. Arterioscler Thromb Vasc Biol 34: 1032-1044, 2014.

18. Sorrentino R, d’Emmanuelle di Villa Bianca R, Lippolis L, Sorrentino L, Autore Gand Pinto A: Involvement of ATP-sensitive potassium channels in a model of a delayed vascular hyporeactivity induced by lipopolysaccharide in rats. Br J Pharmacol 127: 1447-1453, 1999.

19. Li W, Sun W, Yang CH, Hu HZ and Jiang YH: Tanshinong II A protects against lipopolysaccharides-induced endothelial cell injury via Rho/RO kinase pathway. Chin J Integr Med 20: 216-223, 2014.

20. Higai K, Shimamura A and Matsumoto K: Amadori selectin and selectin in vivo lipopolysaccharide infusion on vasoconstrictor function of rat isolated mesentericy, kidney, and aorta. J Pharmacol Exp Ther 306: 538-545, 2003.

21. Coquerel D, Neviere R, Delile E, Mulder P, Marechal X, Montaigne D, Renet S, Remy-Jouet I, Gomez E, Henry JP, do Rego JC, Richard V and Tamion F: Gene deletion of protein tyrosine phosphatase 1B protects against sepsis-induced cardio-vascular dysfunction and mortality. Arterioscler Thromb Vasc Biol 34: 1032-1044, 2014.

22. Coque JF, Smeets EF, Neefjes JJ, Shaffer MA, Cinek T, Today 11: 1034-1040, 2006.

23. Leeuwenberg JF, Smeets EE, Nefjes JJ, Shaffer MA, Cinek T, Jeunhomme TM, Ahrn T and Buurman WA: E-selectin and intercellular adhesion molecule-1 are released by activated human endothelial cells in vitro. Immunity 77: 543-549, 1992.

24. Boldin V, Martin F, Lip GY and Blann AD: Soluble E-selectin in cardiovascular disease and its risk factors. A review of the literature. Thromb Haemost 90: 1007-1020, 2003.

25. Gerczuk PZ, Breckenridge DG, Liles JT, Budas GR, Shryock JC, Belardelli L, Kloer RA and Dai W: An apoptosis signal-regu- lated kinase 1 inhibitor reduces cardiomyocyte apoptosis and infarct size in a rat ischemia-reperfusion model. J Cardiovasc Pharmacol 60: 276-282, 2012.
25. Zhang H, Yu T, Wen L, Wang H, Fei D and Jin C: Curcumin enhances the effectiveness of cisplatin by suppressing CD133+ cancer stem cells in laryngeal carcinoma treatment. Exp Ther Med 6: 1317-1321, 2013.

26. de Pablo R, Monserrat J, Reyes E, Díaz D, Rodríguez-Zapata M, la Hera Ad, Prieto A and Alvarez-Mon M: Sepsis-induced acute respiratory distress syndrome with fatal outcome is associated to increased serum transforming growth factor beta-1 levels. Eur J Intern Med 23: 358-362, 2012.

27. Roy M and Mukherjee S: Reversal of resistance towards cisplatin by curcumin in cervical cancer cells. Asian Pac J Cancer Prev 15: 1403-1410, 2014.

28. Esemuede N, Lee T, Pierre-Paul D, Sumpio BE and Gahtan V: The role of thrombospondin-1 in human disease. J Surg Res 122: 135-142, 2004.

29. Baenziger NL, Brodie GN and Majerus PW: A thrombin-sensitive protein of human platelet membranes. Proc Natl Acad Sci USA 68: 240-243, 1971.

30. DiPietro LA, Nissen NN, Gamelli RL, Koch AE, Pyle JM and Polverini PJ: Thrombospondin 1 synthesis and function in wound repair. Am J Pathol 148: 1851-1860, 1996.

31. Iruela-Arispe ML, Bornstein P and Sage H: Thrombospondin exerts an antiangiogenic effect on cord formation by endothelial cells in vitro. Proc Natl Acad Sci USA 88: 5026-5030, 1991.

32. Hugo C: The thrombospondin 1-TGF-beta axis in fibrotic renal disease. Nephrol Dial Transplant 18: 1241-1245, 2003.

33. Adams JC and Lawler J: The thrombospondins. Cold Spring Harb Perspect Biol 3: a009712, 2011.

34. Chen H, Herndon ME and Lawler J: The cell biology of thrombospondin 1. Matrix Biol 19: 597-614, 2000.

35. Brunner G and Blaktyny R: Extracellular regulation of TGF-beta activity in wound repair: growth factor latency as a sensor mechanism for injury. Thromb Haemost 92: 253-261, 2004.

36. Saltzman AK, Olson TA, Mohanraj D, Carson LF and Ramakrishnan S: Prevention of postoperative adhesions by an antibody to vascular permeability factor/vascular endothelial growth factor in a murine model. Am J Obstet Gynecol 174: 1502-1506, 1996.

37. Zhang XM, Shi PH, Cao SH, Yu JH, Azad J and Ling SC: Expression changes of transforming growth factor-beta1 and thrombospondin-1 in cavernous tissues of diabetic rats. Urol Int 84: 221-225, 2010.

38. McMaken S, Exline MC, Mehta P, Piper M, Wang Y, Fischer SN, Newland CA, Schrader CA, Balser SR, Sarkar A, Baran CP, Marsh CB, Cook CH, Phillips GS and Ali NA: Thrombospondin-1 contributes to mortality in murine sepsis through effects on innate immunity. PLoS One 6: e19654, 2011.

39. Bone RC: Sir Isaac Newton, sepsis, SIRS, and CARS. Crit Care Med 24: 1125-1128, 1996.

40. Daniel C, Wiede J, Krutzsch HC, Ribeiro SM, Roberts DD, Murphy-Ullrich JE and Hugo C: Thrombospondin-1 is a major activator of TGF-beta in fibrotic renal disease in the rat in vivo. Kidney Int 65: 459-468, 2004.

41. Kim HJ, Park SY, Park OJ and Kim YM: Curcumin suppresses migration and proliferation of Hep3B hepatocarcinoma cells through inhibition of the Wnt signaling pathway. Mol Med Rep 8: 282-286, 2013.

42. Redondo S, Santos-Gallego CG, Ganado P, García M, Rico L, Del Rio M and Tejerina T: Acetylsalicylic acid inhibits cell proliferation by involving transforming growth factor-beta. Circulation 107: 626-629, 2003.

43. Ruiz E, Redondo S, Gordillo-Moscoso A and Tejerina T: Pioglitazone induces apoptosis in human vascular smooth muscle cells from diabetic patients involving the transforming growth factor-beta/activin receptor-like kinase-4/5/7/Smad2 signaling pathway. J Pharmocol Exp Ther 321: 431-438, 2007.

44. Murphy-Ullrich JE and Poczatek M: Activation of latent TGF-beta by thrombospondin-1: mechanisms and physiology. Cytokine Growth Factor Rev 11: 59-69, 2000.

45. Garcia-Lazaro JF, Thieringer F, Lüth S, Czochra P, Meyer E, Renteria IB, Galle PR, Lohse AW, Herkel J and Kanzler S: Hepatic over-expression of TGF-beta1 promotes LPS-induced inflammatory cytokine secretion by liver cells and endotoxemic shock. Immunol Lett 101: 217-222, 2005.

46. Bechara RI, Pelaez A, Palacio A, Joshi PC, Hart CM, Brown LA, Raynor R and Guidot DM: Angiotensin II mediates glutathione depletion, transforming growth factor-beta expression, and epithelial barrier dysfunction in the alcoholic rat lung. Am J Physiol Lung Cell Mol Physiol 289: L363-L370, 2005.

47. Xu F, Lin SH, Yang YZ, Guo R, Cao J and Liu Q: The effect of curcumin on sepsis-induced acute lung injury in a rat model through the inhibition of the TGF-beta1/SMAD3 pathway. Int Immunopharmacol 16: 1-6, 2013.

48. Yoshida H, Okumura N, Nishimura Y, Kitagishi Y and Matsuda S: Turmeric and curcumin suppress presenilin 1 protein expression in Jurkat cells. Exp Ther Med 2: 629-632, 2011.

49. Hsu YC, Chen MJ, Yu YM, Ko SY and Chang CC: Suppression of TGF-β1/SMAD pathway and extracellular matrix production in primary keloid fibroblasts by curcuminoids: its potential therapeutic use in the chemoprevention of keloid. Arch Dermatol Res 302: 717-724, 2010.